5.53
+0.22(+4.14%)
Currency In USD
| Previous Close | 5.31 |
| Open | 5.26 |
| Day High | 5.75 |
| Day Low | 5.23 |
| 52-Week High | 29.3 |
| 52-Week Low | 3.81 |
| Volume | 1.41M |
| Average Volume | 2.32M |
| Market Cap | 509.74M |
| PE | -4.94 |
| EPS | -1.12 |
| Moving Average 50 Days | 5.31 |
| Moving Average 200 Days | 13.14 |
| Change | 0.22 |
If you invested $1000 in Myriad Genetics, Inc. (MYGN) 10 years ago, it would be worth $159.97 as of July 02, 2025 at a share price of $5.53. Whereas If you bought $1000 worth of Myriad Genetics, Inc. (MYGN) shares 5 years ago, it would be worth $477.55 as of July 02, 2025 at a share price of $5.53.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Myriad Genetics Announces Early Access to the FirstGene Multiple Prenatal Screen
GlobeNewswire Inc.
Jun 03, 2025 1:00 PM GMT
Screening test provides prenatal risk assessment for common genetic conditions in one blood draw without the need for paternal testing Early access via large-scale clinical study to establish the validity and utility of the FirstGeneTM screen SALT LA
Myriad Genetics Shares New Clinical Data Demonstrating Sensitivity of Precise MRD Across Multiple Cancer Types
GlobeNewswire Inc.
Jun 02, 2025 1:00 PM GMT
MONSTAR-SCREEN-3 study showed 100% detection of circulating tumor DNA (ctDNA) at baseline timepoint, and 60% of patients testing positive one month after surgery had tumor fractions only detectable via ultra-sensitive MRDSALT LAKE CITY, June 02, 202
Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting
GlobeNewswire Inc.
May 27, 2025 8:05 PM GMT
Two Molecular Residual Disease (MRD) studies highlighting clinical data among seven new studies to be shared by Myriad and collaboratorsSALT LAKE CITY, May 27, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular dia